MedTrace Logo

A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in ALS Patients

NCT05407428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2024-10-30

No results posted yet for this study

Summary

This is a prospective study in a cohort of about 45 patients with ALS participating in the Neurosense PrimeC drug study (NCT05357950).

This study aims to evaluate the correlation between oculometric measures and clinical endpoints. Subjects will be evaluated every 2 months during a time period of 18 months. The evaluations will include ALSFRS-R examination, as well as an oculometric evaluation for eye movements.

Conditions

Interventions

OTHER

NeuraLight software-based platform

NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including ALS patients

Sponsors & Collaborators

  • NeuraLight

    lead INDUSTRY

Principal Investigators

  • Vivian Drory, MD · Sackler Faculty of Medicine, Tel Aviv University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2024-10-28
Completion
2024-10-28

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05407428 on ClinicalTrials.gov